Effects of Nicotinamide Adenine Dinucleotide on Older Patients with Heart Failure.
NAD+
adjuvant therapy
clinical study
heart failure
Journal
Reviews in cardiovascular medicine
ISSN: 2153-8174
Titre abrégé: Rev Cardiovasc Med
Pays: Singapore
ID NLM: 100960007
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
received:
04
01
2024
revised:
14
03
2024
accepted:
28
03
2024
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
4
9
2024
Statut:
epublish
Résumé
Heart failure (HF) is the main cause of death in middle-aged and older people and is characterized by high morbidity, high mortality, a high rehospitalization rate, and many high-risk groups. Nicotinamide adenine dinucleotide (NAD Based on using conventional drugs to treat HF, patients (n = 60) were randomized 1:1 to saline and 50 mg NAD Among the 60 patients with HF who were treated with NAD According to the results of this study, it is believed that 7 days of NAD Chinese Clinical Trial Registry (http://www.chictr.org.cn/) ChiCTR2300074326; retrospectively registered on 3 August 2023.
Sections du résumé
Background
UNASSIGNED
Heart failure (HF) is the main cause of death in middle-aged and older people and is characterized by high morbidity, high mortality, a high rehospitalization rate, and many high-risk groups. Nicotinamide adenine dinucleotide (NAD
Methods
UNASSIGNED
Based on using conventional drugs to treat HF, patients (n = 60) were randomized 1:1 to saline and 50 mg NAD
Results
UNASSIGNED
Among the 60 patients with HF who were treated with NAD
Conclusions
UNASSIGNED
According to the results of this study, it is believed that 7 days of NAD
Clinical Trial Registration
UNASSIGNED
Chinese Clinical Trial Registry (http://www.chictr.org.cn/) ChiCTR2300074326; retrospectively registered on 3 August 2023.
Identifiants
pubmed: 39228487
doi: 10.31083/j.rcm2508297
pii: S1530-6550(24)01399-1
pmc: PMC11366984
doi:
Types de publication
Journal Article
Langues
eng
Pagination
297Informations de copyright
Copyright: © 2024 The Author(s). Published by IMR Press.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest. Knature Company (Hefei Knature Biopharm Co., Ltd,) was not involved in this study and the authors declare that the company has no conflict of interest.